Bladder Cancer
Conditions
Interventions
Bladder thermal perfusion chemotherapy with GEM after TURBT:Bladder thermal perfusion chemotherapy
Intravenous chemotherapy with gemcitabine combined with cisplatin after TURBT:Intravenous chemotherapy
Sponsors
Chengdu Xinhua Hospital
Eligibility
Sex/Gender
All
Age
45 Years to 81 Years
Inclusion criteria
Inclusion criteria: (1) Combined with the findings of cystoscopy, pelvic CT/MRI and postoperative pathology, the patient was diagnosed with MIBC. (2) Pathological staging was based on the seventh edition of the International Union Against Cancer TNM staging method in 2009, and the clinical staging of TNM was T2N0M0. (3) Tumors in the bladder triangle, posterior wall, left and right side walls with safe surgical margins, and the patient's tumor margins were confirmed to be negative. (4) Patients who refused radical surgery as well as radiotherapy and were fully informed prior to treatment. (5) Patients treated with TUR-Bt, and all patients treated with postoperative chemotherapy with gemcitabine as the primary chemotherapy agent (systemic chemotherapy or bladder thermal perfusion chemotherapy). (6) No concomitant tumors in other tissues and no abnormalities in liver or kidney function. (7) Patients with BCG allergy, contraindications or refusal to use BCG therapy.
Exclusion criteria
Exclusion criteria: (1) Patients who did not undergo TURBT (2) Patients who died without 2 cycles of chemotherapy after initiation. (3) Patients with distal metastases or the presence of upper urinary tract tumors (4) Patients with non-urological epithelial carcinoma. (5) Patients who failed to complete or interrupted chemotherapy for more than 1 cycle. (6) Patients who have been transferred to another hospital or have a lost visit. (7) Patients who underwent radical cystectomy, radiotherapy and were not treated with GP chemotherapy and gemcitabine thermal perfusion. Translated with www.DeepL.com/Translator (free version)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Recurrence rate;Clinical efficacy; | — |
Countries
China
Contacts
Public ContactYuchi Tong
Chengdu xinhua Hospital
Outcome results
None listed